

## CARsgen appoints Dr Sylvie Peltier as senior Vice President of global regulatory affairs

01 November 2022 | News

With extensive experience and knowledge in clinical and CMC regulatory affairs

China-based startup CARsgen Therapeutics Holdings has announced that DrSylvie Peltier has been appointed as Senior Vice President of Global Regulatory Affairs of the company with effect from October 31st, 2022. She will be responsible for developing global regulatory strategies, leading and driving the company's regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally.

Dr Sylvie has extensive global leadership and hands-on experiences in clinical and Chemistry, Manufacturing and Controls (CMC) regulatory affairs across several multinational pharmaceutical and biopharmaceutical companies.

Prior to joining CARsgen, she served as Vice President, Head of US Regulatory Affairs at MorphoSys US Inc since 2020, and as Head of Regulatory Affairs at Servier Pharmaceuticals LLC from 2018. Before joining Servier Pharmaceuticals LLC, Dr Sylvie served at Cephalon since 2007, an international biopharmaceutical company which was acquired later by TEVA Pharmaceuticals Industries, holding various positions from Senior Director, Europe Regulatory Affairs, CNS/Pain and CMC, Senior Director, US Regulatory Affairs, to Senior Director, Clinical Search Evaluation and Due Diligence. Previously, she worked at Pfizer Regulatory Affairs from 1995.